Advanced SearchSearch Tips
Determination of Sample Sizes of Bivariate Efficacy and Safety Outcomes
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Determination of Sample Sizes of Bivariate Efficacy and Safety Outcomes
Lee, Hyun-Hak; Song, Hae-Hiang;
  PDF(new window)
We consider sample-size determination problem motivated by comparative clinical trials where patient outcomes are characterized by a bivariate outcome of efficacy and safety. Thall and Cheng (1999) presented a sample size methodology for the case of bivariate binary outcomes. We propose a bivariate Wilcoxon-Mann-Whitney(WMW) statistics for sample-size determination for binary outcomes, and this nonparametric method can be equally used to determine sample sizes of ordinal outcomes. The two methods of sample size determination rely on the same testing strategy for the target parameters but differs in the test statistics, an asymptotic bivariate normal statistic of the transformed proportions in Thall and Cheng (1999) and nonparametric bivariate WMW statistic in the other method. Sample sizes are calculated for the two experimental oncology trials, described in Thall and Cheng (1999), and for the first trial example the sample sizes of a bivariate WMW statistic are smaller than those of Thall and Cheng (1999), while for the second trial example the reverse is true.
Sample sizes;bivariate WMW;efficacy and safety;
 Cited by
단변량 및 이변량 순위변수의 비모수적 윌콕슨 검정법에 의한 표본수 결정방법,박해강;송혜향;

응용통계연구, 2009. vol.22. 6, pp.1249-1263 crossref(new window)
Agresti, A. (1984). Analysis of Ordinal Categorical Data, John Wiley & Sons, New York

Birnbaum, Z. W. and Klose, O. M. (1957). Bounds for the variance of the Mann-Whitney statistic, The Annals of Mathematical Statistics, 28, 933-945 crossref(new window)

Bryant, J. and Day, R. (1995). Incorporating toxicity considerations into the design of two-stage phase II clinical trials, Biometrics, 51, 1372-1383 crossref(new window)

Conaway, M. R. and Petroni, G. R. (1995). Bivariate sequential designs for phase II trials, Biometrics, 51, 656-664 crossref(new window)

Conaway, M. R and Petroni, G. R (1996). Designs for phase II trials allowing for a trade-off between response and toxicity, Biometrics, 52, 1375-1386 crossref(new window)

Cook, R J. and Farewell, V. T. (1994). Guidelines for monitoring efficacy and toxicity responses in clinical trials, Biometrics, 50, 1146-1152 crossref(new window)

Cook, R J. (1996). Coupled error spending functions for parallel bivariate sequential tests, Biometrics, 52, 442-450 crossref(new window)

Delong, E. R, Delong, D. M. and Clarke-Pearson, D. L. (1988). Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach, Biometrics, 44, 837-845 crossref(new window)

Hochberg, Y. (1981). On the variance estimate of a Wilcoxon-Mann-Whitney statistic for group ordered data, Communications in Statistics - Theory and Method, A10, 1719-1732 crossref(new window)

Jennison, C. and Turnbull, B. W. (1993). Group sequential tests for bivariate response: Interim analysis of clinical trials with both efficacy and safety endpoints, Biometrics, 49, 741-752 crossref(new window)

Lehmann, E. L. (1975). Nonparametrics: Statistical Methods Based on Ranks, Holden-Day, San Francisco

Levine, M. N., Guyatt, G. H., Gent, M., De Pauw, S., Goodyear, M. D., Hryniuk, W. M., Arnold, A., Findlay, B., Skillings, J. R. and Bramwell, V. H. (1988). Quality of life in stage II breast cancer: An instrument for clinical trials, Journal of Clinical Oncology, 6, 1798-1810 crossref(new window)

Lipsitz, S. R., laird, N. M. and Harrington, D. P. (1990). Maximum likelihood regression methods for paired binary data, Statistics in Medicine, 9, 1517-1525 crossref(new window)

Molenberghs, G. and Lesaffre, E. (1994). Marginal modeling of correlated ordinal data using a multivariate plackett distribution, Journal of the American Statistical Association, 89, 633-644 crossref(new window)

Noether, G. E. (1987). Sample size determination for some common nonparametric tests, Journal of the American Statistical Association, 82, 645-647 crossref(new window)

Norwood, P. K. and Sampson, A. R. (1988). A statistical methodology for postmarketing surveillance of adverse drug reaction reports, Statistics in Medicine, 7, 1023-1030 crossref(new window)

Petri, H., Leufkens, H., Naus, J., Silkens, R., van Hessen, P. and Urquhart, J. (1990). Rapid method for estimating the risk of acutely controversial side effects of prescription drugs, Journal of Clinical Epidemiology, 43,433-439 crossref(new window)

Pocock, S. J., Geller, N. L. and Tsiatis, A. A. (1987). The analysis of multiple endpoints in clinical trials, Biometrics, 43, 487-498 crossref(new window)

Simonoff, J. S., Hochberg, Y. and Reiser, B. (1986). Alternative estimation procedures for Pr(X < Y) in categorized data, Biometrics, 42, 895-907 crossref(new window)

Thall, P. F. and Cheng, S. C. (1999). Treatment comparisons based on two-dimensional safety and efficacy alternatives in oncology trials, Biometrics, 55, 746-753 crossref(new window)

Thall, P. F. and l.achin, J. M. (1988). Analysis of recurrent events:Nonparametric methods for randominterval count data, Journal of the American Statistical Association, 83, 339-347 crossref(new window)

Thall, P. F. and Russell, K. E. (1998). A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase 1/11 clinical trials, Biometrics, 54, 251-264 crossref(new window)

Tubert-Bitter, P., Bloch, D. A. and Raynauld, J. (1995). Comparing the bivariate effects of toxicity and efficacy of treatments, Statistics in Medicine, 14, 1129-1141 crossref(new window)